• 1
    Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20: 72937.
  • 2
    Cockerell OC, Johnson AL, Sander JWAS, et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346: 1404.
  • 3
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342: 3149.
  • 4
    Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004;75: 137681.
  • 5
    Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999;34: 10922.
  • 6
    Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002;11: 7784.
  • 7
    Berg A, Shinnar S. Do seizures beget seizures? An assessment of the clinical relevance in humans. J Clin Neurophysiol 1997;14: 10110.
  • 8
    Semah F, Picot M-C, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51: 125662.
  • 9
    Sloviter RS. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the “dormant basket cell” hypothesis and its possible relevance to temporal lobe epilepsy. Hippocampus 1991;1: 4166.
  • 10
    Brooks-Kayal AR, Shumate MD, et al. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med 1998;4: 116672.
  • 11
    Proper EA, Hoogland G, Kappen SM, et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2002;125: 324.
  • 12
    Sisodiya SM. Mechanism of antiepileptic drug resistance. Opin Neurol 2003;16: 197201.
  • 13
    Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301: 714.
  • 14
    Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62: 385427.
  • 15
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2: 4858.
  • 16
    Van Veen HW, Konings WN. Multidrug transporters from bacteria to man: similarities in structure and function. Semin Cancer Biol 1997;8: 18391.
  • 17
    Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11: 115666.
  • 18
    Silverman JA. Multidrug-resistance transporters. Pharmaceut Biotech 1999;12: 35386.
  • 19
    Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461: 23762.
  • 20
    Callen DF, Baker E, Simmers RN, et al. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987;77: 1424.
  • 21
    Borst P. Introduction: multidrug resistant proteins. Am Cancer Biol 1997;8: 1314.
  • 22
    Dicato M, Duhem C, Pauly M, et al. Multidrug resistance: molecular and clinical aspects. Cytokines Cell Mol Ther 1997;3: 91100.
  • 23
    McKeegan KS, Borges-Walmsley MI, Walmsley AR, et al. The structure and function of drug pumps: an update. Trends Microbiol 2003;11: 219.
  • 24
    Ueda K, Taguchi Y, Morishima M. How does P-glycoprotein recognize its substrates? Semin Cancer Biol 1997;8: 4249.
  • 25
    Chang G. Multidrug resistance ABC transporters. FEBS Lett 2003;555: 1025.
  • 26
    Schinkel AH, Smit JJM, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77: 491502.
  • 27
    Schinkel AH, Wagenaar E, Mol CAAM, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97: 25174.
  • 28
    Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94: 402833.
  • 29
    Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998;36: 913.
  • 30
    Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8: 16170.
  • 31
    Schuetz EG, Umbenhauer DR, Yasuda K, et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 2000;57: 18897.
  • 32
    Ford JM, Yang J-M, Hait WN. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 1996;87: 338.
  • 33
    Sharom JF. The P-glycoprotein efflux pump: how does it transport drugs? J Membrane Biol 1997;160: 16175.
  • 34
    Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251: 25261.
  • 35
    Rodriguez I, Abernethy DR, Woosley RL. P-glycoprotein in clinical cardiology. Circulation 1999;99: 4724.
  • 36
    Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotech 1993;12: 171212.
  • 37
    Avendaño C, Menéndez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002;9: 15993.
  • 38
    Dalton WS. Is p-glycoprotein a potential target for reversing clinical drug resistance? Curr Opin Oncol 1994;6: 595600.
  • 39
    Lum BL, Gosland MP. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol/Oncol Clin N Am 1995;9: 31936.
  • 40
    Sarkadi B, Müller M. Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 1997;8: 17182.
  • 41
    Tan B, Picnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12: 4508.
  • 42
    Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84: 2659.
  • 43
    Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 1988;48: 19269.
  • 44
    Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38: 127787.
  • 45
    Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at the blood-brain barrier sites. Proc Nat Acad Sci USA 1989;86: 6958.
  • 46
    Beaulieu E, Demeule M, Ghitescu L, et al. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997;326: 53944.
  • 47
    Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000;38: 6974.
  • 48
    Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101: 28994.
  • 49
    Sparreboom A, Van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94: 20315.
  • 50
    Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug permeability barrier. Proc Natl Acad Sci USA 1999;96: 39005.
  • 51
    Zhang Z-J, Saito T, Kimura Y, et al. Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice. Brain Res 2000;852: 11626.
  • 52
    Burt RK, Thorgeirsson SS. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 1988;80: 13836.
  • 53
    Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrates specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13: 12934.
  • 54
    Schuetz EG, Schinkel AH, Relling MV, et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996;93: 40015.
  • 55
    Johnstone RW, Ruefli AA, Tainton KM, et al. A role for P-glycoprotein in regulating cell death. Leukemia Lymphoma 2000;38: 111.
  • 56
    Pallis M, Turzanski J, Grundy M, et al. Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. Br J Haematol 2003;120: 100916.
  • 57
    Kight KM, Hallene KL, Marchi N, et al. Expression of multidrug resistance proteins in “epileptic” neurons [Abstract]. Epilepsia 2003;44(suppl 9):340.
  • 58
    Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 2002;57: 36580.
  • 59
    Demeule M, Régina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharm 2002;38: 33948.
  • 60
    Pardridge WM, Golden PL, Kang YS, et al. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 1997;68: 127885.
  • 61
    Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma consideration. Pharmacol Rev 2001;53: 56996.
  • 62
    Golden PL, Pardridge WM. P-glycoprotein on astrocytes foot processes of unfixed isolated human brain capillaries. Brain Res 1999;819: 1436.
  • 63
    Ballerini P, Di Lorio P, Ciccarelli R, et al. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. NeurorReport 2002;13: 178992.
  • 64
    Matsumoto T, Tani E, Kaba K, et al. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 1991;74: 4606.
  • 65
    Dietzmann K, Bossanyi PV, Franke DS. Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma. Zentralbl Pathol 1994;140: 14953.
  • 66
    Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999;10: 343741.
  • 67
    Barrand MA, Robertson KJ, Von Weikersthal SF. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 1995;374: 17983.
  • 68
    Regina A, Koman A, Piciotti M, et al. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 1998;71: 70515.
  • 69
    Seegers U, Potschka H, Löscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 2002;43: 67584.
  • 70
    Kwan P, Sills GJ, Butler E, et al. Differential expression of multidrug resistance genes in naïve rat brain. Neurosci Lett 2003;339: 336.
  • 71
    Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002;41: 8192.
  • 72
    Cole SPC, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998;20: 93140.
  • 73
    Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92: 1298302.
  • 74
    Seelig A, Li Blatter X, Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharm Ther 2000;38: 11121.
  • 75
    Rappa G, Finch RA, Sartorelli AC, et al. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models. Biochem Pharm 1999;58: 55762.
  • 76
    Wijnholds J. Drug resistance caused by multidrug resistance-associated proteins. Novartis Found Sympos 2002;243: 6979.
  • 77
    Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002;302: 40715.
  • 78
    Borst P, Evers R, Kool M, et al. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461: 34757.
  • 79
    Langmann T, Mauerer R, Zahn A, et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 2003;49: 2308.
  • 80
    Gao B, Hagenbuch B, Kullak-Ublick GA, et al. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000;294: 739.
  • 81
    Hoffmeyer S, Burk O, Von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97: 34738.
  • 82
    Hitzl M, Drescher S, Van Der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11: 2938.
  • 83
    Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter, 1:1 pharmacogenetics study. Lancet 2002;359: 306.
  • 84
    Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002;72: 57283.
  • 85
    Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002;12: 53541.
  • 86
    Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70: 18999.
  • 87
    Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin: a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72: 20919.
  • 88
    Johne A, Köpke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002;72: 58494.
  • 89
    Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2002;13: 8995.
  • 90
    Mai I, Störmer E, Goldammer M, Johne A, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003;43: 11017.
  • 91
    Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;358: 3834.
  • 92
    Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001;11: 721.
  • 93
    Tang K, Ngoi S-M, Gwee P-C, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12: 43750.
  • 94
    Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13: 48194.
  • 95
    Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001;11: 17584.
  • 96
    Gottesman MM, Hrycyna CA, Schoenlein PV, et al. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995;29: 60749.
  • 97
    Babb TL, Brown WJ. Pathological findings in epilepsy. In: EngelJJr, ed. Surgical treatment of the epilepsies. New York : Raven Press, 1993: 51140.
  • 98
    Jutila L, Immonen A, Mervaala E, et al. Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients. J Neurol Neurosurg Psychiatry 2002;73: 48694.
  • 99
    Tishler DM, Weinberg KI, Hinton DR, et al. MD1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36: 16.
  • 100
    Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multidrug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42: 15016.
  • 101
    D'Giano C, Sevlever G, Lazarowski A, et al. Expression of P-glycoprotein and related proteins in brain of patients with refractory temporal-lobe epilepsy (TLE). Epilepsia 1997;38(suppl 8):87.
  • 102
    Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125: 2231.
  • 103
    Aronica E, Gorter JA, Ramkema M, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004;45: 44151.
  • 104
    Sisodiya SM, Lin W-R, Squier MV, et al. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357: 423.
  • 105
    Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118: 41729.
  • 106
    Lazarowski A, Sevlever G, Taratuto A, et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999;21: 7314.
  • 107
    Lazarowski A, Lubieniecki F, Camarero HT et al. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol 2004;102: 306.
  • 108
    Lardizabal DV, Jacobson B, Ying Z, et al. Multidrug resistance-1 (MDR1) protein expression in Rasmussen encephalitis [Abstract]. Epilepsia 2003;44(suppl 9):356.
  • 109
    Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348: 14428.
  • 110
    Tan NCK, Heron SE, Scheffer IE, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004;63: 10902.
  • 111
    Zimprich F, Sunder-Plassmann R, Stogmann E, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004;63: 10879.
  • 112
    Sisodiya SM, Thom M. Widespread upregulation of drug-resistance proteins in fatal human status epilepticus. Epilepsia 2003;44: 2614.
  • 113
    Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999;126: 50916.
  • 114
    Volk HA, Burkhardt K, Potschka H, et al. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004;123: 7519.
  • 115
    Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002;22: 58339.
  • 116
    Kwan P, Sills GJ, Butler E, et al. Regional expression of multi-drug resistance genes in genetically epilepsy-prone rat brain following a single audiogenic seizure. Epilepsia 2002;43: 131823.
  • 117
    Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A co-ordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49: 3118.
  • 118
    Seegers U, Potschka H, Löscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002;451: 14955.
  • 119
    Wang Y, Zhou D, Wang B, et al. A kindling model of pharmacoresistant temporal lobe epilepsy in Sprague-Dawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia 2003;44: 57488.
  • 120
    Owen A, Pirmohamed M, Tetty JN, et al. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51: 3459.
  • 121
    Sills GJ, Kwan P, Butler E, et al. P-glycoprotein mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002;3: 42732.
  • 122
    Potschka H, Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42: 123140.
  • 123
    Potschka H, Fedrowitz M, Löscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12: 355760.
  • 124
    Potschka H, Fedrowitz M, Löscher. P-glycoprotein-medicated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002;327: 1736.
  • 125
    Potschka H, Löscher W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 2001;12: 23879.
  • 126
    Potschka H, Fedrowitz M, Löscher. Multidrug resistance protein MRP2 contributes to blood-barrier function and restricts antiepileptic drug delivery. J Pharmacol Exp Ther 2003;306: 12431.
  • 127
    Bakos E, Evers R, Sinko E, et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000;57: 7608.
  • 128
    Marroni M, Agrawal ML, Kight K, et al. Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes. Neuroscience 2003;121: 60517.
  • 129
    Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(suppl 5):S28.
  • 130
    Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998;10: 1719.
  • 131
    MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48: 83341.
  • 132
    Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001;42: 51524.
  • 133
    Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997;49: 9918.
  • 134
    Stables JP, Bertram EH, White HS, et al. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 2002;43: 141020.
  • 135
    Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003;60(suppl 4):S212.
  • 136
    Brodie MJ, Leach JP. Success or failure with antiepileptic drug therapy: beyond empiricism? Neurology 2003;60: 1623.
  • 137
    Chen C, Chin JE, Clark DP, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47: 3819.